Equity Overview
Price & Market Data
Price: $0.491
Daily Change: +$0.072 / 14.66%
Range: $0.395 - $0.499
Market Cap: $12,883,082
Volume: 322,796
Performance Metrics
1 Week: 27.35%
1 Month: -13.45%
3 Months: -44.11%
6 Months: -67.38%
1 Year: -69.93%
YTD: -40.34%
Company Details
Employees: 43
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.